-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Quotrix System der Börse DüsseldorfEURSymbol ICY-
INCYTE CORPBörse Quotrix System der Börse DüsseldorfEURSymbol ICY
-
INCYTE CORPBörse Gettex System der Börse MünchenEURSymbol ICY
-
INCYTE CORPBörse Börse DüsseldorfEURSymbol ICY
-
INCYTE CORPBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol ICY
-
INCYTE CORPBörse Börse StuttgartEURSymbol ICY
-
ISIN US45337C1027 WKN: 896133USDSymbol INCY
-
EURSymbol ICY
-
EURSymbol ICY
-
EURSymbol ICY
-
USD
-
BRL
-
Symbol ICY
Währung
EUR
Börse
Quotrix System der Börse Düsseldorf Zeitzone: America/Sao_Paulo
Firmenname
Incyte Corporation
Marktkapitalisierung
16.213.590.089 (+- 24%)
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
20.156.391.424 oder 13.297.000.000 oder 15.187.378.842
Mitarbeiter
1.890 (+- 23%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.456 oder 2.324 Mitarbeiter
Anzahl Aktien
218.996.090
KGV
44.82 (+- 6%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
47.64 oder 42
EBITDA 466.960.992
PEGRatio 0.9315
Buchwert 10.922
Aktionärsstruktur der Incyte Corporation
Portrait der Incyte Aktie
Das Unternehmen Incyte Corporation aus USA beschäftigt 1.890 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Incyte Corporation ist in mehr als 43 ETFs enthalten und somit eine vermutlich durchschnittlich bekannte Aktie. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet Incyte mit 3,08% im ETF.
Entdecke die 6 ETFs in denen Incyte Corporation am höchsten gewichtet ist Insgesamt in 43 ETFs enthalten
Dir gefallen die Informationen zu Incyte?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Incyte?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Incyte?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Incyte?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
38 News & Informationen zur Incyte Aktie
4 Bullish Stock Picks After Earnings With Huge Potential Upside – 24
JMP Securities has come out with a few stock picks that it thinks will outperform in the coming months.
Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth
Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.
Incyte Corporation 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:INCY)
The following slide deck was published by Incyte Corporation in conjunction with their 2021 Q2 earnings call.
Incyte tops Q1 forecast; Jakafi revenue outlook lowered (NASDAQ:INCY)
Incyte (INCY) reports Q2 2021 results and provides an update on its development portfolio.Total revenues rose marginally by 2.6% to $705.7M, surpassing analyst estimates of…
Incyte EPS beats by $0.06, beats on revenue (NASDAQ:INCY)
Incyte (INCY): Q2 Non-GAAP EPS of $0.80 beats by $0.06; GAAP EPS of $0.67 beats by $0.12.Revenue of $705.71M (+2.6% Y/Y) beats by $18.76M.Jakafi (ruxolitinib) revenues of $529M in Q2…
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis …
2 Stocks Under $100 You Can Buy and Hold Forever
Drugmakers can be excellent long-term holdings.
MorphoSys : Reports Second Quarter and First Half 2021 Results (Form 6-K)
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to receive… | July 29, 2021
3 S&P 500 Laggards Ready to Run
Among the 60 or so laggards, some will finish strong while others will slip further off the pace. Investors looking for names with comeback potential…
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
/PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the…
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
INDIANAPOLIS, July 29, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Admi…
Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Polycythemia Vera Therapeutics Market to Surpass US$ 1,516.5 Million by 2028, Says Coherent Market Insights (CMI)
SEATTLE, July 27, 2021 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global polycythemia vera therapeutics market is estimated to be…
Were Hedge Funds Right About Rogers Communications Inc. (RCI)?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter,…
Incyte : Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte Corporation today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding its Biologics License Application for retifanlimab, an intravenous… | July 23, 2021
Incyte Provides Regulatory Update On Retifanlimab For The Treatment Of Certain Patients With Squamous Cell Carcinoma Of The Anal Canal (SCAC)
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its
DGAP-News: Il settore delle biotecnologie -2-
scienza. Il team di gestione di BB Biotech intende sfruttare questa tendenza in maniera mirata, ampliando le proprie
competenze negli ambiti di advanced analytics e intelligenza artificiale…. | July 23, 2021
Big Rebound as Fear Subsides and Netflix Reports
Stocks Analysis by Zacks Investment Research covering: Alcoa Corp, Marvell Technology Group Ltd, CSX Corporation, Texas Instruments Incorporated. Read Zacks Investment Research's latest article on Investing.com
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
Should I Avoid Expeditors International of Washington (EXPD)?
In this article we will analyze whether Expeditors International of Washington (NASDAQ:EXPD) is a good investment right now by following the lead of some…
Incyte Announces Positive Phase 3 REACH3 Study Data Published In NEJM For Ruxolitinib (Jakafi®) In Chronic Graft-Versus-Host Disease
Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM)
Do Hedge Funds Love Affirm Holdings, Inc. (AFRM)?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred…
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) advancing …
Global Graft Versus Host Disease (GVHD): Market Size from 2018 to 2030 and Overview of Treatment Practices and Emerging Drugs
DUBLIN, June 29, 2021 /PRNewswire/ — The 'Graft Versus Host Disease (GVHD) – Market Insight, Epidemiology and Market Forecast – 2030' report has …
+++Börsen-Ticker+++ – Schweizer Börse tendiert seitwärts – Credit Suisse legt deutlich zu
Die Schweizer Börse hat am Freitag einen Marschhalt eingelegt.
Incyte : Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration , which reviewed the Biologics License Application for… | June 24, 2021
Hedge Funds Have Never Been This Bullish On The AES Corporation (AES)
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed…
Incyte: What Falling Off A (Patent) Cliff Looks Like (NASDAQ:INCY)
A better understanding is needed of the financial implications for Incyte with its major product, Jakafi, facing LOE in 2027.
Drugmakers Are Vying for a Multibillion-Dollar Market
Too bad there are issues with side effects.
A Short Delay Is Still Bad News for AbbVie
Rinvoq's FDA approval decision could be a sign the drug class is under investigation.
Incyte Corporation (INCY) Presents at AACR Virtual Meeting 2021 – Slideshow (NASDAQ:INCY)
The following slide deck was published by Incyte Corporation in conjunction with this event.
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 14) 10X …
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 12) …
MorphoSys And Incyte : Health Canada Accepts NDS For Anti-CD19 Antibody Tafasitamab
(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) said that Health Canada has accepted the New Drug Submission or NDS for tafasitamab, an anti-CD19…
13.01.2020 Morphosys schließt Milliardendeal für Krebsmittel Tafasitamab mit Incyte Zum Artikel
03.03.2020 Morphosys darf bei Krebsmittel Tafasitamab mit Incyte zusammenarbeiten Zum Artikel